SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Battalion Oil Corp. engages in the acquisition, production, exploration, and development of liquids-rich oil and natural gas assets in the Delaware Basin. The company was founded in 1987 and is headquartered in Houston, TX.

Battalion Oil Corp - Ordinary Shares (New)

Battalion Oil Corp ($BATL) is experiencing a massive rally, fueled by reports of Iran threatening or closing the Strait of Hormuz, leading to anticipation of surging oil prices. The low-float energy stock is seeing intense community discussion around a potential short squeeze, driven by extremely high borrow fees and expectations of reaching $20-$50+.

POET Technologies, Inc. engages in the designing, developing, manufacturing and sale of opto-electronic solutions for the sensing, data communications and telecommunications markets. It developed POET Optical Interposer platform, which allows the integration of electronic and photonic devices into a single multi-chip module. The company was founded on November 14, 1985 and is headquartered in Toronto, Canada.

POET Technologies Inc

POET Technologies is trending amid surging interest in photonics solutions for AI data centers, buoyed by recent institutional investment, a strategic partnership mention from Quantum Computing, and NVIDIA's broader sector validation. The community is actively discussing POET's optical interposer technology as a key enabler for next-generation high-speed interconnects and eagerly awaits major customer announcements.

Indonesia Energy Corp. Ltd. operates as an oil and gas, exploration, and production company. It engages in oil and gas assets portfolio with a mix between medium-sized producing blocks and exploration blocks with significant resources. Its portfolio includes Kruh, Citarum, and Rangkas Area. The company was founded by James J. Huang and Wirawan Jusuf in 2014 and is headquartered in Jakarta, Indonesia.

Indonesia Energy Corp Ltd

Indonesia Energy Corp Ltd (INDO) is trending as the Middle East conflict escalates, with reports of the Strait of Hormuz closure fueling expectations of soaring oil prices, though the community is actively discussing why INDO isn't matching the significant runs seen in peer oil stocks like BATL.

MongoDB, Inc. engages in the development and provision of a general-purpose database platform. The firm's products include MongoDB Enterprise Advanced, MongoDB Atlas, and Community Server. It also offers professional services including consulting and training. The company was founded by Eliot Horowitz, Dwight A. Merriman, Kevin P. Ryan, and Geir Magnusson Jr. in November 2007 and is headquartered in New York, NY.

MongoDB Inc - Ordinary Shares - Class A

MongoDB Inc

MongoDB is trending following a significant stock drop, driven by cautious short-term guidance and recent leadership transitions, despite strong past earnings. This has ignited community debate, with some citing broader software sector pressures and growth concerns, while others see it as an exaggerated sell-off presenting a long-term buying opportunity given its AI and database platform.

AST Spacemobile, Inc. engages in building a broadband cellular network in space to operate directly with standard, unmodified mobile devices based on an extensive IP and patent portfolio. It focuses on providing mobile broadband services with global coverage to all end-users, without the need to purchase special equipment. The company was founded by Abel Avellan on May 31, 2017 and is headquartered in Midland, TX.

AST SpaceMobile Inc - Ordinary Shares - Class A

AST SpaceMobile Inc

AST SpaceMobile is trending following a positive earnings call that included accelerating satellite deployment plans, optimistic revenue growth guidance, and new partnerships with global telecom providers. The community is actively discussing the company's full funding for its constellation, expected additional announcements, and its emerging role in defense and space-based AI, prompting strong bullish sentiment against persistent skepticism.

Archer Aviation, Inc. engages in the development of electric vertical take-off and landing (eVTOL) aircraft. The company was founded by Brett Adcock and Adam Goldstein on October 16, 2018, and is headquartered in San Jose, CA.

Archer Aviation Inc - Ordinary Shares - Class A

Archer Aviation Inc

Archer Aviation is trending as the first eVTOL company to achieve 100% FAA Means of Compliance acceptance, a pivotal regulatory milestone that bulls believe significantly de-risks its path to 2026 piloted operations, while community discussion continues around its Q4 loss and ongoing capital requirements.

AeroVironment, Inc. engages in the design, development, and production of multi-domain robotic systems and related services for government agencies and businesses. It operates through the following business segments: UnCrewed Systems, Loitering Munitions Systems, and MacCready Work. The UnCrewed Systems segment focuses primarily on small UAS products designed to operate reliably at lower altitudes in a wide range of environmental conditions. The Loitering Munitions Systems segment focuses primarily on tube-launched aircraft that deploy with the push of a button, fly at higher speeds than small UAS products, and perform either effects delivery or reconnaissance missions, and related support services including training, spare parts, product repair, and product replacement. The MacCready Works segment focuses on customer-funded research and development in the areas of HAPS, robotics, sensors, software analytics, data intelligence, and connectivity. The company was founded by Paul B. MacCready, Jr. in July 1971 and is headquartered in Arlington, VA.

AeroVironment Inc.

AeroVironment is trending after a significant sell-off, driven by a Raymond James downgrade citing the recompeting of a $1.4 billion Space Force contract. Yet, many in the community perceive this as an overreaction and a buying opportunity, emphasizing other bullish analyst targets and robust demand for drones amid global conflicts.

Red Cat Holdings, Inc. provides products, services and solutions to the drone industry. It also engages in the provision of distributed data storage, analytics and services for the drone industry.The firm product include Dronebox, which is a blockchain technology that records, stores and analyzes flight data and information from a drone. It operates through the Enterprise Segment. The Enterprise Segment will focus on developing a hardware enabled software platform of services and solutions to government and commercial enterprises and the military. The company was founded by Jeffrey M. Thompson in February 1984 and is headquartered in San Juan, Puerto Rico.

Red Cat Holdings Inc

Red Cat Holdings is trending amid escalating geopolitical tensions driving increased demand for drone and autonomous defense solutions, with the community actively discussing potential short squeeze opportunities fueled by high volume and optimistic contract prospects.

Gorilla Technology Group, Inc. engages in the provision of video intelligence, Internet of Things (IoT) security, edge AI data analytics, and operational technology security solutions and services in Asia Pacific. It operates through the following segments: Video IoT, Security Convergence, and Other. The company was founded by Spincer Koh in May 2001 and is headquartered in London, the United Kingdom.

Gorilla Technology Group Inc

Gorilla Technology Group is trending following its full-year 2025 earnings, which reported record revenue exceeding $100 million and significant profitability improvements, fueling community debate over its perceived undervaluation and ambitious $7B+ AI infrastructure pipeline, while skeptics point to past execution concerns and low institutional ownership.

Trump Media & Technology Group Corp. engages in operating social media and in the technology business. Its brands include TRUTH Social, TMTG+ and TMTG News. The company was founded on March 28, 2024 and is headquartered in Sarasota, FL.

Trump Media & Technology Group Corp.

Trump Media & Technology Group (DJT) is trending due to the Trump administration's ongoing military strikes against Iran, which has ignited polarized community discussions. While proponents hail the actions as vital for global security, critics widely dismiss it as an "illegal war" and a distraction from domestic issues and the "Epstein files," fueling intense debate and contributing to the stock's volatility.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

<ul class="summary-bullets"><li>The ongoing GPS trial is an overall survival study and final analysis is expected once 80 deaths have occurred.</li><li>As of Dec. 26, 72 deaths have occurred, the company said earlier, highlighting that it had previously expected 80 patient deaths to occur by December end.</li><li>Maxim analyst Jason McCarthy previously noted that delays in an event-driven trial like SELLAS’ could be suggestive of extended survival benefit from GPS.</li></ul>Shares of Sellas Life Sciences (SLS) garnered the spotlight on Stocktwits on Friday as retail traders contemplated the company’s upcoming results from its late-stage trial for Galinpepimut-S (GPS). &nbsp;SELLAS is currently evaluating Galinpepimut-S (GPS) as a potential maintenance therapy in patients with Acute Myeloid Leukemia who have achieved complete remission following second-line salvage therapy.AML is a fast-growing cancer of the blood and bone marrow where immature white blood cells build up, crowding out healthy cells, leading to fatigue, infections, and bleeding.<h2 class="st-heading-2">How Did Stocktwits Users React?</h2>A Stocktwits user expressed optimism for data from the trial spurring a rally. “Till then it’s the accumulation game,” he said.<stembedurl>https://www.stocktwits.com/Heypentaco/message/646154506</stembedurl>Another opined that the GPS will be worth over $180/share to big pharma companies looking to buy Sellas.<stembedurl>https://www.stocktwits.com/67X_ROI_Q1_2026/message/646149937</stembedurl>Another user opined that now is the time to buy more shares of the company.<stembedurl>https://www.stocktwits.com/Polsky/message/646158337</stembedurl>Overall, retail sentiment around SLS stock stayed within the ‘extremely bullish’ territory over the past 24 hours, while message volume remained at ‘high’ levels. According to Stocktwits data, retail chatter around the stock has increased by about 453% over the past 90 days.<h2 class="st-heading-2">The GPS Trial</h2>The ongoing GPS trial is an overall survival study and final analysis is expected once 80 deaths have occurred. As of Dec. 26, 72 deaths have occurred, the company said earlier, highlighting that it had previously expected 80 patient deaths to occur by December end.“While the 80th event has not yet occurred, and we remain fully blinded, every passing month may increase the probability of a successful study as highlighted by key opinion leaders in our recent R&amp;D event. Conclusive data will follow the unblinding and analyses of the study results,” SELLAS CEO Angelos Stergiou then said.Maxim analyst Jason McCarthy then noted that delays in an event-driven trial like SELLAS’ could be suggestive of extended survival benefit from GPS.According to data from Koyfin, all three of the analysts covering SELLAS rate it ‘Buy’ or higher. The stock has an average price target of $6.83, hinting at further potential upside.<a href="https://stocktwits.com/symbol/SLS">SLS shares</a> have more than quadrupled over the past 12 months.Read More: <a href="https://stocktwits.com/news-articles/markets/equity/why-are-us-bank-stocks-seeing-heavy-selloffs-today/cZTcHyHRITv">Why Are US Banks Seeing Heavy Selloffs Today?</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

Global stock market chart and trading board - stock photo

SLS Stokes Retail Anticipation For Breakout Rally — What’s Driving The Interest?

SELLAS is currently evaluating Galinpepimut-S (GPS) as a potential maintenance therapy in patients with Acute Myeloid Leukemia who have achieved complete remission following second-line salvage therapy.

Equity

SELLAS is currently evaluating Galinpepimut-S (GPS) as a potential maintenance therapy in patients with Acute Myeloid Leukemia who have achieved complete remission following second-line salvage therapy.


<ul class="summary-bullets"><li>Sellas’ CEO referenced the company’s Phase 3 REGAL trial in a LinkedIn post, following its December update that the final analysis was approaching for GPS as a therapy in AML.</li><li>Anson Funds Management recently disclosed that it held a 4.9% stake in Sellas.</li><li>Last month, Sellas partnered with IMPACT-AML to advance AML treatments.</li></ul>Sellas Life Sciences Group Inc. (SLS) generated significant retail buzz on Monday as the stock shot up more than 15% to its highest levels in more than a month.According to Stocktwits data, message volume on the platform increased nearly 170% over the past 24 hours.<h2 class="st-heading-2">Retail Bullish On Potential Phase 3 REGAL Trial Results</h2>Retail sentiment for <a href="https://stocktwits.com/symbol/SLS">SLS</a> on Stocktwits remained in the ‘bullish’ territory over the past 24 hours, amid ‘high’ message volumes.<img src="https://news.stocktwits-cdn.com/Sellas_jpg_9c62bbaf10.webp" alt="Sellas.jpg">On Sunday, Angelos M. Stergiou, President and CEO of Sellas, made a reference to the company’s Phase 3 REGAL trial in a <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://www.linkedin.com/feed/update/urn:li:activity:7431478609229438976/">post</a> on LinkedIn. Last December, the company <a href="https://stocktwits.com/news-articles/markets/equity/sellas-life-sciences-group-stock-soars-as-it-nears-final-analysis-in-cancer-study/cL7dROARExt">said</a> it was nearing the final analysis from its Phase 3 REGAL trial for Galinpepimut-S (GPS) as a potential maintenance therapy in Acute Myeloid Leukemia (AML).AML is a fast-growing blood and bone marrow cancer in which abnormal white blood cells crowd out healthy cells.One user said the REGAL data was the “ultimate catalyst.”<stembedurl>https://stocktwits.com/kay91667/message/645624253</stembedurl>Another user said that “REGAL Phase 3 remains event-driven and approaching its final trigger.”<stembedurl>https://stocktwits.com/G_Trade/message/645600596</stembedurl>According to an SEC filing last week, Anson Funds Management disclosed that it held a 4.9% stake in the company, prompting a user to call it a “very exciting time” for shareholders.<stembedurl>https://stocktwits.com/Az2fl2025/message/645612860</stembedurl><h2 class="st-heading-2">IMPACT-AML Partnership</h2>Last month, Sellas partnered with IMPACT-AML, a European initiative dedicated to advancing AML treatments, to conduct a multi-site European clinical study of SLS009, the company’s selective CDK9 inhibitor.The stock came under some selling pressure in January over dilution fears after the company <a href="https://stocktwits.com/news-articles/markets/equity/sellas-life-sciences-stock-falls-for-fourth-straight-session/cmU2FjBR4dH">said</a> it received about $26.5 million from the exercise of common stock warrants.Year-to-date, SLS shares have gained around 3%.Read also: <a href="https://stocktwits.com/news-articles/markets/equity/why-did-sw-ip-pkg-stocks-slump-today/cZRtU4BR4yp">Why Did SW, IP, PKG Stocks Slump Today?</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

Representative image of a trending stock chart.

Sellas Life Sciences Draws Significant Retail Buzz As Traders Eye REGAL Phase 3 Catalyst – SLS Stock Soars 15%

According to Stocktwits data, message volume on the platform surrounding the stock increased nearly 170% over the past 24 hours.

SELLAS Life Sciences Group Target of Unusually Large Options Trading (NASDAQ:SLS)

SELLAS Life Sciences Group, Inc. (NASDAQ:SLS - Get Free Report) saw unusually large options trading activity on Monday. Stock traders acquired 42,324 call options on the company. This is an increase...

Notable Thursday Option Activity: SLS, MDGL, ZG

Looking at options trading activity among components of the Russell 3000 index, there is noteworthy activity today in SELLAS Life Sciences Group Inc (Symbol: SLS), where a total volume of 38,228...

SELLAS Life Sciences Group (NASDAQ:SLS) Shares Up 9.8% - Here's Why

SELLAS Life Sciences Group (NASDAQ:SLS) Trading Up 9.8% - Here's What Happened...

SELLAS Life Sciences Group (NASDAQ:SLS) Shares Gap Down - Should You Sell?

SELLAS Life Sciences Group (NASDAQ:SLS) Shares Gap Down - Here's Why...

SELLAS Life Sciences Group, Inc. (NASDAQ:SLS) Short Interest Down 14.9% in January

SELLAS Life Sciences Group, Inc. (NASDAQ:SLS - Get Free Report) saw a significant decline in short interest in January. As of January 15th, there was short interest totaling 42,044,430 shares, a...

SELLAS Life Sciences Group (NASDAQ:SLS) Shares Down 7.4% - Should You Sell?

SELLAS Life Sciences Group (NASDAQ:SLS) Trading Down 7.4% - Here's What Happened...

SELLAS Life Sciences Group (NASDAQ:SLS) Trading 9.2% Higher - Still a Buy?

SELLAS Life Sciences Group (NASDAQ:SLS) Shares Up 9.2% - Here's Why...

SELLAS Life Sciences Group, Inc. (NASDAQ:SLS) Short Interest Up 22.1% in December

SELLAS Life Sciences Group, Inc. (NASDAQ:SLS - Get Free Report) saw a large growth in short interest during the month of December. As of December 31st, there was short interest totaling 49,429,420...

SELLAS Life Sciences Group, Inc. is a clinical stage biopharmaceutical company, which engages in the development and commercialization of immunotherapeutic for cancer indications. Its product pipeline includes galinpepimut-S. The company was founded by Angelos M. Stergiou on April 3, 2006 and is headquartered in New York, NY.

SELLAS Life Sciences Group Inc

Beat EPS and revenue

Beat EPS, miss revenue

Miss EPS, beat revenue

Miss EPS and revenue

What do you expect from $MDB earnings today?

Stocktwits

Stocktwits Polls

High anticipation builds for Phase 3 GPS trial results, with extended patient survival and "unlimited dosing" cited as strong signals of unprecedented efficacy.

Intense user sentiment suggests short sellers are cornered, with many predicting a massive squeeze as available shares dwindle and price climbs.

The stock successfully closed above the crucial $5 mark, a key milestone believed to unlock institutional buying and signal further upward momentum.

Strong technicals, including RSI and MACD signals, indicate a significant breakout from multi-year consolidation, pushing towards new 52-week highs.

Current Price	$5.05
Prev Close	$4.93
Open	$4.70
Dividend Yield	0.00%
50-Day Moving Average	$3.81
Beta	0.75
Avg. Volume	11.53M
PE Ratio	-17.18

52-Week High	$5.18
52-Week Low	$0.9516
Market Capitalization	$702.24M
EPS (Annual)	-$0.5046
Price to Book	13.51
Revenue Per Employee	$0.00

SLS
SELLAS Life Sciences Group Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest SLS News

SLSSELLAS Life Sciences Group Inc